ERBB2 and neoplasm: In two cases the HER2 amplification can be accurately measured using circulating tumor DNA (ctDNA) from plasma, resulting in a sensitivity and specificity of 0.2 and 1, with an estimated likelihood ratio of 20 (p-value 0.48; supplementary file Fig. S4C).